Replimune price target raised to $20 from $16 at BMO Capital
bullish
Public signal · 1-minute delayed
Source-backed market context you can read and share without an account.
bullish
What happened, with direct paths to the underlying reporting
BMO Capital raises REPL's price target to $20; current price is $12.86.
Target: $20
Posted price: $12.86
Analyst firm: BMO Capital
Transparent limits for an AI-generated research aid
StockNews.AI groups source reporting, classifies the event, and measures subsequent price movement. This is informational research, not investment advice. Prices may be delayed or unavailable.